BREKIYA

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Peripheral Ischemia Following Coadministration with Strong CYP3A4 Inhibitors [see Boxed Warning and Warnings and Precautions (5.1) ] Myocardial Ischemia and/or Infarction, Other Adverse Cardiac Events, and Fatalities [see Warnings and Precautions (5.2) ] Cerebrovascular Adverse Reactions and Fatalities [see Warnings and Precautions (5.3) ] Other Vasospasm Related Adverse Reactions [see Warnings and Precautions (5.4) ] Increase in Blood Pressure [see Warnings and Precautions (5.5) ] Medication Overuse Headache [see Warnings and Precautions (5.6) ] Preterm Labor [see Warnings and Precautions (5.7) ] Fibrotic Complications [see Warnings and Precautions (5.8) ] Hypersensitivity [see Warnings and Precautions (5.9) ] The following adverse reactions associated with the use of dihydroergotamine were identified in clinical studies or postmarketing reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the drug exposure. Serious cardiac events, including some that have been fatal, have occurred following use of dihydroergotamine. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation [see Contraindications (4) and Warnings and Precautions (5.3) ]. Fibrotic complications have been reported in association with long term use of injectable dihydroergotamine mesylate [see Warnings and Precautions (5.8) ]. Vasospasm, paresthesia, hypertension, dizziness, anxiety, dyspnea, headache, flushing, diarrhea, rash, increased sweating, and pleural and retroperitoneal fibrosis occurred after long-term use of dihydroergotamine. Cases of myocardial infarction and stroke have been reported following the use of dihydroergotamine [see Warnings and Precautions (5.2) ]. Serious cardiac events (including fatal) that have been reported with dihydroergotamine mesylate injection use include coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, ventricular fibrillation. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

4 CONTRAINDICATIONS BREKIYA is contraindicated in patients: with concomitant use of strong CYP3A4 inhibitors [see Warnings and Precautions (5.1) and Drug Interactions (7.1) ] with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina [see Warnings and Precautions (5.4) ] with uncontrolled hypertension [see Warnings and Precautions (5.5) ] with peripheral arterial disease with sepsis following vascular surgery with severe hepatic impairment with severe renal impairment with known hypersensitivity to dihydroergotamine, ergot alkaloids, latex, or any of the ingredients in BREKIYA [see Warnings and Precautions (5.9) ] with recent use (i.e., within 24 hours) of other 5-HT1 agonists, ergotamine-containing or ergot-type medications [see Drug Interactions (7.2) ] with concomitant use of peripheral and central vasoconstrictors because the combination may result in additive or synergistic elevation of blood pressure [see Warnings and Precautions (5.5) ] Concomitant use of strong CYP3A4 inhibitors ( 4 ) Ischemic heart disease or coronary artery vasospasm ( 4 ) Uncontrolled hypertension, peripheral arterial diseases, sepsis, following vascular surgery, or severe hepatic or renal impairment ( 4 ) Concomitant use of other 5-HT 1 agonists or ergotamine-containing or ergot-type medications within 24 hours ( 4 ) Hypersensitivity to dihydroergotamine, ergot alkaloids, latex, or any of the ingredients in BREKIYA (4) Concomitant use with peripheral and central vasoconstrictors ( 4 )

11 DESCRIPTION BREKIYA (dihydroergotamine mesylate) injection is an ergotamine derivative. Dihydroergotamine mesylate is a white or almost white, crystalline powder. It is slightly soluble in water and chloroform and sparingly soluble in methanol. The chemical name for dihydroergotamine mesylate is ergotaman-3´,6´,18-trione,9,10-dihydro-12´-hydroxy-2´-methyl-5´-(phenylmethyl) monomethanesulfonate (salt). Its molecular weight is 679.8g/mol and its molecular formula is C 33 H 37 N 5 O 5 ∙CH 4 O 3 S. The chemical structure is BREKIYA is a clear, colorless, sterile solution supplied in 1 mL single-dose autoinjector for subcutaneous administration. Each mL contains 1 mg dihydroergotamine mesylate, USP (equivalent to 0.86 mg of dihydroergotamine). BREKIYA also contains ethanol, USP 6.1% by volume; glycerin, USP 15% by weight; water for injection, USP; may contain methanesulfonic acid and/or sodium hydroxide, NF for pH adjustment. pH range is 3.4 to 4.9. 1

2 DOSAGE AND ADMINISTRATION For subcutaneous injection only. ( 2.1 ) Recommended dosage is 1 mg administered subcutaneously as a single 1 mL autoinjector. ( 2.1 ) Do not exceed 3 mg (3 doses) in a 24-hour period. ( 2.1 ) Do not exceed 6 mg (6 doses) in a week. ( 2.1 ) Prior to initiation, a cardiovascular evaluation is recommended. ( 2.2 ) 2.1 Recommended Dosage BREKIYA autoinjector is for subcutaneous injection only. The recommended dose of BREKIYA is 1 mg administered subcutaneously via a single 1 mL autoinjector. The dose may be repeated, as needed, at 1-hour intervals to a total maximum of 3 mg (3 doses) in a 24-hour period. Do not exceed 6 mg (6 doses) total in a week. 2.2 Assessment Prior to First Dose Prior to initiation of BREKIYA, a cardiovascular evaluation is recommended [see Warnings and Precautions (5.3) ] . For patients with risk factors predictive of coronary artery disease who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of BREKIYA take place in the setting of an equipped healthcare facility. 2.3 Important Administration Instructions See the “Instructions for Use” for detailed steps for administering the subcutaneous injection using the autoinjector. Preparation BREKIYA is a prefilled, single-dose disposable autoinjector intended to be given subcutaneously into the skin of the middle thigh. Rotate injection sites. Choose an injection site at least 2 inches away from the last injection site. Do not inject into moles, scars, birthmarks, or areas where the skin is tender, bruised, red, or hard. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Carefully examine the liquid medication for discoloration, cloudiness, floating flakes or particles. Administer only if clear and colorless. Administration Remove the red needle cap by pulling it straight off. Position the autoinjector straight onto the cleaned injection site with the white safety guard resting on the skin. Push the autoinjector down and press and release the gray activation button to start the injection. A “click” will sound when the injection starts. The autoinjector takes approximately 10 seconds to deliver the dose; when the viewing window is fully blocked (completely blue), the full dose has been administered.

9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance BREKIYA contains dihydroergotamine (as the mesylate salt), which is not a controlled substance. 9.2 Abuse Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Currently available data have not demonstrated drug abuse with dihydroergotamine. However, cases of drug abuse in patients on other forms of ergot therapy have been reported. 9.3 Dependence Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Currently available data have not demonstrated physical or psychological dependence with dihydroergotamine. However, cases of psychological dependence in patients on other forms of ergot therapy have been reported.

10 OVERDOSAGE Symptoms Excessive doses of dihydroergotamine may result in peripheral signs and symptoms of ergotism. In general, the symptoms of an acute BREKIYA overdose may be similar to those of an ergotamine overdose, although there may be less pronounced nausea and vomiting with BREKIYA. The symptoms of an ergotamine overdose include the following: numbness, tingling, pain, and cyanosis of the extremities associated with diminished or absent peripheral pulses; respiratory depression; an increase and/or decrease in blood pressure, usually in that order; confusion, delirium, convulsions, and coma; and/or some degree of nausea, vomiting, and abdominal pain. In laboratory animals, dihydroergotamine was lethal when given at intravenous doses of 44 mg/kg in mice, 130 mg/kg in rats, and 37 mg/kg in rabbits. Treatment Treatment includes discontinuance of the drug, local application of warmth to the affected area, the administration of vasodilators, and nursing care to prevent tissue damage. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

7 DRUG INTERACTIONS Beta Blockers/Nicotine: May potentiate/provoke vasoconstriction. ( 7.3 , 7.5 ) Selective Serotonin Reuptake Inhibitors: Weakness, hyperreflexia, and incoordination may occur with coadministration. ( 7.6 ) 7.1 CYP3A4 Inhibitors There have been rare reports of serious adverse events in connection with the coadministration of intravenous administration of dihydroergotamine and strong CYP3A4 inhibitors resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities [see Warnings and Precautions (5.1) ]. The use of strong CYP3A4 inhibitors with BREKIYA is contraindicated [see Contraindications (4) ]. Administer moderate CYP3A4 inhibitors with caution. 7.2 Triptans Triptans (serotonin [5-HT 1B/1D receptor agonists) have been reported to cause coronary artery vasospasm, and its effect could be additive with BREKIYA. Therefore, triptans and BREKIYA should not be taken within 24 hours of each other [see Contraindications (4) ]. 7.3 Beta Blockers There have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. 7.4 Vasoconstrictors BREKIYA is contraindicated for use with peripheral and central vasoconstrictors because the combination may cause synergistic elevation of blood pressure [see Warnings and Precautions (5.5) ]. 7.5 Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy [see Warnings and Precautions (5.2 , 5.4 )] . 7.6 Selective Serotonin Reuptake Inhibitors Weakness, hyperreflexia, and incoordination have been reported rarely when 5-HT 1 agonists have been co-administered with selective serotonin reuptake inhibitors (SSRI’s) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline).

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dihydroergotamine binds with high affinity to 5-HT 1Dα and 5-HT 1Dβ receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT 1D receptors. 12.2 Pharmacodynamics Significant elevation in blood pressure has been reported in patients treated with dihydroergotamine with and without a history of hypertension [see Warnings and Precautions (5.5) ]. Dihydroergotamine possesses oxytocic properties [see Warnings and Precautions (5.7) ]. 12.3 Pharmacokinetics Absorption Following BREKIYA administration, the mean maximum plasma concentration was 3.8 ng/mL, and the median time from dosing to maximum plasma concentration was approximately 0.4 hours. Distribution Dihydroergotamine mesylate is 93% plasma protein bound. The apparent steady-state volume of distribution is approximately 800 liters. Elimination Metabolism Four dihydroergotamine mesylate metabolites have been identified in human plasma following oral administration. The major metabolite, 8´-β-hydroxydihydroergotamine, exhibits affinity equivalent to its parent for adrenergic and 5-HT receptors and demonstrates equivalent potency in several venoconstrictor activity models, in vivo and in vitro . The other metabolites (i.e., dihydrolysergic acid, dihydrolysergic amide, and a metabolite formed by oxidative opening of the proline ring) are of minor importance. Following nasal administration, total metabolites represent only 20% to 30% of plasma AUC. Quantitative pharmacokinetic characterization of the four metabolites has not been performed. Excretion The major excretory route of dihydroergotamine is via the bile in the feces. The total body clearance is 1.5 L/min which reflects mainly hepatic clearance. Only 6% to 7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection. The renal clearance (0.1 L/min) is unaffected by the route of dihydroergotamine administration. The decline of plasma dihydroergotamine after intramuscular or intravenous administration is multi-exponential with a terminal half-life of about 9 hours. Specific Populations No studies have been conducted on the effect of renal or hepatic impairment, gender, race, or ethnicity on dihydroergotamine pharmacokinetics [see Contraindications (4) ]. Drug Interaction Studies Pharmacokinetic interactions have been reported in patients treated orally with other ergot alkaloids (e.g., increased levels of ergotamine) and macrolide antibiotics, presumably due to inhibition of cytochrome P450 3A metabolism of the alkaloids. Dihydroergotamine has also been shown to be an inhibitor of cytochrome P450 3A catalyzed reactions and rare reports of ergotism have been obtained from patients treated with dihydroergotamine and macrolide antibiotics (e.g., clarithromycin, erythromycin), and in patients treated with dihydroergotamine and protease inhibitors (e.g., ritonavir), presumably due to inhibition of cytochrome P450 3A metabolism of ergotamine [see Contraindications (4) ].

12.1 Mechanism of Action Dihydroergotamine binds with high affinity to 5-HT 1Dα and 5-HT 1Dβ receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT 1D receptors.

12.2 Pharmacodynamics Significant elevation in blood pressure has been reported in patients treated with dihydroergotamine with and without a history of hypertension [see Warnings and Precautions (5.5) ]. Dihydroergotamine possesses oxytocic properties [see Warnings and Precautions (5.7) ].

12.3 Pharmacokinetics Absorption Following BREKIYA administration, the mean maximum plasma concentration was 3.8 ng/mL, and the median time from dosing to maximum plasma concentration was approximately 0.4 hours. Distribution Dihydroergotamine mesylate is 93% plasma protein bound. The apparent steady-state volume of distribution is approximately 800 liters. Elimination Metabolism Four dihydroergotamine mesylate metabolites have been identified in human plasma following oral administration. The major metabolite, 8´-β-hydroxydihydroergotamine, exhibits affinity equivalent to its parent for adrenergic and 5-HT receptors and demonstrates equivalent potency in several venoconstrictor activity models, in vivo and in vitro . The other metabolites (i.e., dihydrolysergic acid, dihydrolysergic amide, and a metabolite formed by oxidative opening of the proline ring) are of minor importance. Following nasal administration, total metabolites represent only 20% to 30% of plasma AUC. Quantitative pharmacokinetic characterization of the four metabolites has not been performed. Excretion The major excretory route of dihydroergotamine is via the bile in the feces. The total body clearance is 1.5 L/min which reflects mainly hepatic clearance. Only 6% to 7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection. The renal clearance (0.1 L/min) is unaffected by the route of dihydroergotamine administration. The decline of plasma dihydroergotamine after intramuscular or intravenous administration is multi-exponential with a terminal half-life of about 9 hours. Specific Populations No studies have been conducted on the effect of renal or hepatic impairment, gender, race, or ethnicity on dihydroergotamine pharmacokinetics [see Contraindications (4) ]. Drug Interaction Studies Pharmacokinetic interactions have been reported in patients treated orally with other ergot alkaloids (e.g., increased levels of ergotamine) and macrolide antibiotics, presumably due to inhibition of cytochrome P450 3A metabolism of the alkaloids. Dihydroergotamine has also been shown to be an inhibitor of cytochrome P450 3A catalyzed reactions and rare reports of ergotism have been obtained from patients treated with dihydroergotamine and macrolide antibiotics (e.g., clarithromycin, erythromycin), and in patients treated with dihydroergotamine and protease inhibitors (e.g., ritonavir), presumably due to inhibition of cytochrome P450 3A metabolism of ergotamine [see Contraindications (4) ].

20250515

1

3 DOSAGE FORMS AND STRENGTHS Injection: 1 mg/mL dihydroergotamine mesylate as a clear, colorless solution in a 1 mL single-dose autoinjector. Injection: 1 mg/mL dihydroergotamine mesylate as a 1 mL single-dose autoinjector. ( 3 )

BREKIYA Dihydroergotamine Mesylate DIHYDROERGOTAMINE MESYLATE DIHYDROERGOTAMINE ALCOHOL GLYCERIN WATER METHANESULFONIC ACID SODIUM HYDROXIDE

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In a 2-year mouse carcinogenicity study, subcutaneous (SC) administration of dihydroergotamine mesylate (0, 0.5, 1.5 or 5 mg/kg/day) resulted in an increased incidence of fibrosarcoma at the injection sites in males and females at the high dose. The higher dose not associated with an increase in tumors (1.5 mg/kg/day) is approximately 2 times the recommended human dose (RHD) of 3 mg/day SC on a body surface area (mg/m 2 ) basis. In a 2-year rat carcinogenicity study, intranasal administration of dihydroergotamine mesylate (0, 0.4, 0.8 or 1.6 mg/day for 13 weeks, followed by 0, 0.08, 0.24 or 0.8 mg/day for the remainder of the study) did not result in an increase in tumors. Mutagenesis Dihydroergotamine mesylate was negative in an in vitro mutagenicity (Ames) assay and positive in in vitro chromosomal aberration (V79 Chinese hamster cell assay with metabolic activation, and human peripheral blood lymphocyte) assays. Dihydroergotamine was negative in in vivo micronucleus assays in mouse and hamster. Impairment of Fertility Intranasal administration of dihydroergotamine to rats at doses up to 1.6 mg/day was not associated with adverse effects on fertility.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In a 2-year mouse carcinogenicity study, subcutaneous (SC) administration of dihydroergotamine mesylate (0, 0.5, 1.5 or 5 mg/kg/day) resulted in an increased incidence of fibrosarcoma at the injection sites in males and females at the high dose. The higher dose not associated with an increase in tumors (1.5 mg/kg/day) is approximately 2 times the recommended human dose (RHD) of 3 mg/day SC on a body surface area (mg/m 2 ) basis. In a 2-year rat carcinogenicity study, intranasal administration of dihydroergotamine mesylate (0, 0.4, 0.8 or 1.6 mg/day for 13 weeks, followed by 0, 0.08, 0.24 or 0.8 mg/day for the remainder of the study) did not result in an increase in tumors. Mutagenesis Dihydroergotamine mesylate was negative in an in vitro mutagenicity (Ames) assay and positive in in vitro chromosomal aberration (V79 Chinese hamster cell assay with metabolic activation, and human peripheral blood lymphocyte) assays. Dihydroergotamine was negative in in vivo micronucleus assays in mouse and hamster. Impairment of Fertility Intranasal administration of dihydroergotamine to rats at doses up to 1.6 mg/day was not associated with adverse effects on fertility.

NDA215400

BREKIYA

Dihydroergotamine Mesylate

64896-509

HUMAN PRESCRIPTION DRUG

SUBCUTANEOUS

PRINCIPAL DISPLAY PANEL NDC 64896-509-01 BREKIYA ® (dihydroergotamine mesylate) injection, 1 mg/mL Rx only Autoinjector Label Amneal Pharmaceuticals LLC 1 NDC 64896-509-01 BREKIYA ® (dihydroergotamine mesylate) injection, 1 mg/mL Rx only Pouch Amneal Pharmaceuticals LLC 1 NDC 64896-509-02 BREKIYA ® (dihydroergotamine mesylate) injection, 1 mg/mL Rx only Carton Amneal Pharmaceuticals LLC 1

INSTRUCTIONS FOR USE This Instructions for Use contains information on how to inject BREKIYA. If there are any questions concerning the use of BREKIYA autoinjector, ask your healthcare provider, pharmacist or visit www.brekiya.com. Important Information You Need to Know Before Injecting BREKIYA Warnings BREKIYA is for injection under the skin (subcutaneous) only. The rigid needle shield of the BREKIYA autoinjector contains a needle cover (located inside the cap) that contains dry natural rubber, which is made from latex. Tell your healthcare provider if you are allergic to latex. Do not remove the red needle cap until you are ready to inject BREKIYA. Inject BREKIYA right away after removing the red needle cap. Do not inject BREKIYA if the autoinjector appears damaged, if the expiration date has passed, if the liquid medicine is cloudy, discolored or has floating flakes or particles. Do not throw away (dispose of) the autoinjector into the household trash. Throw away (dispose of) the autoinjector into a FDA-cleared sharps disposal container. Dosing Follow your healthcare provider’s dosing instructions for how often to inject BREKIYA autoinjector. Each autoinjector contains 1 dose (1 mg) of BREKIYA. After your first dose of BREKIYA, you may give yourself 2 more doses (for a total of 3 mg) as needed. Wait at least 1 hour between doses. Do not inject more than 3 doses (3 mg) of BREKIYA in 1 day (24-hour) period. Do not inject more than 6 doses (6 mg) during a 1-week (7-day) period. Storing BREKIYA Autoinjector Store the BREKIYA autoinjector at room temperature between 68°F to 77°F (20°C to 25°C). Protect BREKIYA from light. Keep BREKIYA in the carton until ready to use. Do not refrigerate or freeze BREKIYA. Keep BREKIYA and all medicines out of the reach of children. Autoinjector Parts This autoinjector is a prefilled single dose (1 time use), disposable device that gives a 1 mg subcutaneous (under the skin) injection of BREKIYA. Figure A shows a new and used autoinjector. Figure A Preparing to Inject BREKIYA Step 1: Wash Hands and Gather Supplies 1.1 Before you begin, wash your hands with soap and water (See Figure B). Figure B 1.2 Gather the following supplies (See Figure C): BREKIYA autoinjector foil pouch (inside carton) Alcohol swab Cotton balls or gauze Sharps container [See “Throwing Away (Disposing of) BREKIYA”] Figure C Step 2: Remove and Inspect the Autoinjector 2.1 Tear open the foil pouch from the notch to remove the autoinjector (See Figure D). Figure D 2.2 Check the expiration date printed on the autoinjector (See Figure E). Do not use the autoinjector if the expiration date has passed. 2.3 Check the liquid medicine in BREKIYA by looking through the viewing window (See Figure E). The liquid medicine in BREKIYA should be clear and colorless. It is normal to see one or more air bubbles. Do not inject if the liquid medicine appears cloudy, discolored, or has floating flakes or particles. Do not inject if the autoinjector appears to be damaged or broken. Figure E Step 3: Select and Prepare Injection Site 3.1 Locate your injection site. BREKIYA autoinjector should be injected into the skin in the middle of your thigh (See Figure F). Do not inject into moles, scars, birthmarks, or areas where the skin is tender, bruised, red, or hard. Do not inject through clothing. Do not inject into the same spot 2 times in a row. Important: This injection should be at least 2 inches away from the last injection site. Figure F 3.2 Clean the injection site with an alcohol swab (See Figure G). Wait for the injection site to air dry before giving the injection. Do not touch the clean injection site again before you inject BREKIYA. Figure G Injecting BREKIYA Step 4: Remove Red Needle Cap and Position the Autoinjector 4.1 Remove the red needle cap by pulling it straight off (See Figure H) and throw it away in the household trash. Do not bend or twist the cap while removing. Do not touch the white safety guard after the red needle cap is removed. Figure H 4.2 Position the autoinjector straight onto the cleaned injection site with the white safety guard resting on the skin (See Figure I). Figure I Step 5: Give Injection 5.1 Push the autoinjector down against the skin until you do not see the white safety guard (See Figure J). Important: Keep downward pressure on the skin throughout the injection process. Figure J 5.2 Press and release the gray activation button to start the injection (See Figure K). You will hear a “click” sound when the injection starts. Be Patient. Do not lift the autoinjector after the first click. Important: If you do not hear a “click” when you press the gray activation button, make sure that the autoinjector is pressed down against the skin, then try again. Figure K 5.3 Hold the autoinjector down against the skin for at least 10 seconds to make sure you get the full dose of BREKIYA (See Figure L). Note: You may hear a second “click”, which means you are close to the end of the injection. Whether or not you hear a second “click” you must hold down the autoinjector against your skin for at least 10 seconds. Do not lift up the autoinjector early. Figure L 5.4 Make sure the injection is finished by looking at the viewing window. The viewing window will turn completely blue (See Figure M) when the full dose of BREKIYA has been given. Note: Even if the inspection window is not completely blue, do not try to use the autoinjector again. Figure M Throwing Away (Disposing of) BREKIYA Autoinjector Step 6: Lift and Throw away (dispose of) 6.1 Lift the autoinjector straight up, away from the skin. The white safety guard will drop down and lock over the needle (See Figure N). Note: If you think that you have not received the full dose, do not repeat the injection using a new autoinjector. Call your healthcare provider right away for assistance. Figure N 6.2 Throw away (dispose of) the used autoinjector into a FDA-cleared sharps disposal container (See Figure O). Do not throw away (dispose of) the autoinjector into household trash. Figure O 6.3 Treat the injection site as needed (See Figure P). It is normal to see a drop of blood or medicine at the injection site. It will not affect your dose. Figure P Additional Information on how to Throw Away (Dispose of) BREKIYA Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container. Distributed by: Amneal Specialty, a division of Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Ahmedabad 382213, INDIA For more information or to report side-effects, call 1-877-835-5472. Rev. 05-2025-00 This Instructions for Use have been approved by the U.S. Food and Drug Administration Issued: 05/2025 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use). Serious and/or Life-Threatening Reactions with Coadministration of CYP3A4 Inhibitors Inform patients that serious and/or life-threatening peripheral ischemia (cerebral ischemia and/or ischemia of the extremities) has been associated with the coadministration of dihydroergotamine and strong CYP3A4 inhibitors, [see Contraindications ( 4 ) , Warnings and Precautions ( 5.1 ) , and Drug Interactions ( 7.1 ) ] . Myocardial Ischemia and/or Infarction, Other Cardiac Events, Cerebrovascular Events, and Fatalities Inform patients of the risk for serious cardiac, cerebrovascular, and other vasospasm related events. Advise patients to notify their healthcare provider if they develop any risk factors or symptoms while taking BREKIYA. Inform patients that nicotine may provoke vasoconstriction predisposing to a greater ischemic response [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 )]. Increase in Blood Pressure Inform patients of the risk for significant elevation in blood pressure [see Warnings and Precautions (5.5) ] . Medication Overuse Headache Inform patients that use of drugs to treat migraine attacks for 10 or more days per month may lead to an exacerbation of headache, and encourage patients to record headache frequency and drug use (e.g., by keeping a headache diary) [see Warnings and Precautions ( 5.6 ) ] . Hypersensitivity Inform patients that the rigid needle shield of the BREKIYA autoinjector contains a needle cover (located inside the cap) that contains dry natural rubber, which is made from latex, and can cause allergic reactions in latex-sensitive individuals [see Warnings and Precautions (5.9) ]. Drug Interactions Advise patients to inform their healthcare providers if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions [see Drug Interactions ( 7 ) ] . Pregnancy Advise patients of the risk for preterm birth. Advise women to inform their healthcare provider if they are pregnant or intend to become pregnant [see Warnings and Precautions ( 5.7 ) , Use in Specific Populations ( 8.1 ) ]. Lactation Advise patients not to breastfeed during treatment with BREKIYA [ see Use in Specific Populations ( 8.2 ) ]. Important Administration Instructions Advise patients on the proper use of BREKIYA prior to the initial use and instruct them to read the Instructions for Use [see Dosage and Administration (2.3) ] . For more information, call 1-877-835-5472. BREKIYA ® is a registered trademark of Amneal Pharmaceuticals LLC. Distributed by: Amneal Specialty, a division of Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Ahmedabad 382213, INDIA Rev. 05-2025-01

MEDICATION GUIDE BREKIYA ® [breh-kee-yah] (dihydroergotamine mesylate) injection, for subcutaneous use What is the most important information I should know about BREKIYA? BREKIYA can cause serious side effects, including: Serious problems with blood circulation to your legs and feet (peripheral ischemia) . BREKIYA can cause peripheral ischemia when you take it with certain medicines known as CYP3A4 inhibitors. Peripheral ischemia may lead to a stroke and death. Stop taking BREKIYA and get emergency medical help right away if you have any of the following symptoms: cramping and pain in your legs or hips feeling of heaviness or tightness in your leg muscles burning or aching pain in your feet or toes while resting numbness, tingling, or weakness in your legs cold feeling or color changes in 1 or both legs or feet slurred speech sudden weakness Do not take medicines known as strong CYP3A4 inhibitors, such as: ritonavir indinavir clarithromycin itraconazole nelfinavir erythromycin ketoconazole These are not all of the medicines that could affect how BREKIYA works. Your healthcare provider can tell you if it is safe to take BREKIYA with other medicines. What is BREKIYA? BREKIYA is a prescription medicine used for the acute treatment of migraine with or without aura and acute cluster headaches in adults. BREKIYA is not used to prevent migraine. BREKIYA is not used to treat other types of headaches such as hemiplegic migraines (that make you unable to move on one side of your body) or basilar migraines (rare form of migraine with aura). It is not known if BREKIYA is safe and effective in children. Who should not take BREKIYA? Do not use BREKIYA if you: are taking medicines known as strong CYP3A4 inhibitors. have heart problems or a history of heart problems. have uncontrolled high blood pressure. have narrowing of blood vessels in your legs, arms, stomach, or kidneys (peripheral vascular disease). have sepsis. have had vascular surgery. have severe liver problems. have severe kidney problems. are allergic to dihydroergotamine, ergot alkaloids, latex, or any of the ingredients in BREKIYA. See the end of this Medication Guide for a complete list of ingredients in BREKIYA. have taken any of the following medicines in the last 24 hours: sumatriptan almotriptan eletriptan frovatriptan naratriptan rizatriptan ergotamine or ergotamine-type medicines zolmitriptan have taken any medicines that constrict your blood vessels or raise your blood pressure. Ask your healthcare provider if you are not sure if you are taking any of these medicines. Your healthcare provider can tell you if it is safe to take BREKIYA with other medicines. Before you take BREKIYA, tell your healthcare provider about all of your medical conditions, including if you: have high blood pressure. have liver problems. have kidney problems. have risk factors for heart disease. You have a higher risk for heart disease if you: have high blood pressure have high cholesterol levels smoke are overweight have diabetes have a family history of heart disease are taking medicines known as strong CYP3A4 inhibitors. are pregnant or plan to become pregnant. BREKIYA may cause preterm labor. BREKIYA should be avoided during pregnancy. Talk to your healthcare provider right away if you are pregnant or want to become pregnant. are breastfeeding or plan to breastfeed. BREKIYA may reduce breast milk supply and pass into your breast milk. BREKIYA may be harmful to your baby. Do not breastfeed your baby while taking BREKIYA and for 3 days after you use BREKIYA. Talk with your healthcare provider about the best way to feed your baby if you take BREKIYA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your healthcare provider will decide if you can take BREKIYA with your other medicines. Especially tell your healthcare provider if you take: sumatriptan fluconazole propranolol or other medicines that can lower your heart rate ergot-type medicine grapefruit juice any medicines that can increase your blood pressure saquinavir zileuton selective serotonin reuptake inhibitors nefazodone nicotine These are not all of the medicines that could affect how BREKIYA works. Your healthcare provider can tell you if it is safe to take BREKIYA with other medicines. How should I use BREKIYA? Certain people should take their first dose of BREKIYA in their healthcare provider’s office or in another medical setting. Ask your healthcare provider if you should take your first dose in a medical setting. BREKIYA is for injection under the skin (subcutaneous) only. Use BREKIYA exactly as your healthcare provider tells you to use it. See the detailed Instructions for Use that comes with BREKIYA for information about how to use BREKIYA. Each autoinjector contains 1 dose (1 mg) of BREKIYA. If your headache comes back after the first complete dose, you may give yourself up to 2 more doses as needed. Wait at least 1 hour between doses. Do not inject more than 3 doses (3 mg) of BREKIYA in a 24-hour period or 6 doses (6 mg) in a 1-week (7 day) period. Using BREKIYA for 10 or more days in 1 month may make your headache worse. You should write down when you have headaches and when you take BREKIYA so that you can talk with your healthcare provider about how BREKIYA is working for you. If you use too much BREKIYA, call your healthcare provider or the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. What are the possible side effects of BREKIYA ? BREKIYA can cause serious side effects, including: See “What is the most important information I should know about BREKIYA?” Heart attack and other heart problems. Heart problems may lead to death. Stop taking BREKIYA and get emergency medical help right away if you have any of the following symptoms of a heart attack: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded BREKIYA is not for people with risk factors for heart disease unless a heart exam is done and shows no problem. See “Before you take BREKIYA, tell your healthcare provider about all of your medical conditions, including if you:” for the risk factors for heart disease. Stroke. Stop using BREKIYA and get emergency medical help right away if you have any of the following symptoms of a stroke: face drooping unusual weakness or numbness slurred speech Changes in color or sensation in your fingers and toes (Raynaud’s syndrome). Stomach and intestinal problems (gastrointestinal and colonic ischemic events). Symptoms of gastrointestinal and colonic ischemic events include: sudden or severe stomach pain constipation or diarrhea stomach pain after meals bloody diarrhea weight loss fever nausea or vomiting Increased blood pressure. Medicine overuse headache. Some people who use too much BREKIYA may make their headaches worse (medicine overuse headache). If your headaches get worse, your healthcare provider may decide to stop your treatment with BREKIYA. Preterm labor. Tissue changes (fibrotic complications). Inflammation and fiber-like tissue that is not normal (fibrosis) can occur around the lungs and stomach. The most common but serious side effects of BREKIYA are heart problems that happen but may lead to death. These heart problems include: temporary squeezing of arteries that supply the heart (coronary artery vasospasm) temporary decrease of blood flow to the heart (transient myocardial ischemia) heart rhythm problems (ventricular tachycardia and ventricular fibrillation) Symptoms of these heart problems include: See “ heart attack and other heart problems .” numbness or tingling in your fingers and toes. muscle pain or cramps in your arms and legs. weakness in your legs. temporary speeding or slowing of your heart rate. swelling or itching. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of BREKIYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store BREKIYA ? Store BREKIYA at room temperature between 68°F to 77°F (20°C to 25°C). Do not refrigerate or freeze BREKIYA. Protect BREKIYA from light. Keep BREKIYA in the original pack until ready to use. Keep BREKIYA and all medicines out of the reach of children. General information about the safe and effective use of BREKIYA . Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BREKIYA for a condition for which it was not prescribed. Do not give BREKIYA to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about BREKIYA that is written for health professionals. What are the ingredients in BREKIYA ? Active ingredient: dihydroergotamine mesylate, USP Inactive ingredients: ethanol, glycerin, water for injection, methanesulfonic acid or sodium hydroxide. Distributed by: Amneal Specialty, a division of Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Ahmedabad 382213, INDIA For more information or to report side-effects, call 1-877-835-5472. Rev. 05-2025-00 This Medication Guide has been approved by the U.S. Food and Drug Administration Issued: 05/2025

8.2 Lactation Risk Summary There are no data on the presence of dihydroergotamine in human milk; however, ergotamine, a related drug, is excreted in human milk. There are reports of vomiting, diarrhea, weak pulse, and unstable blood pressure in breastfed infants exposed to ergotamine. BREKIYA may reduce milk supply because it may decrease prolactin levels. Because of the potential for reduced milk supply and serious adverse events in the breastfed infant, including diarrhea, vomiting, weak pulse, and unstable blood pressure; advise patients not to breastfeed during treatment with BREKIYA and for 3 days after the last dose. Breast milk supply during this time should be pumped and discarded.

8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.

8.1 Pregnancy Risk Summary Available data from published literature indicate an increased risk of preterm delivery with dihydroergotamine, the active moiety in BREKIYA, use during pregnancy. Avoid use of BREKIYA during pregnancy [see Warnings and Precautions (5.9) ] . Data collected over decades have shown no increased risk of major birth defects or miscarriage with the use of dihydroergotamine mesylate during pregnancy . In animal reproduction studies, adverse effects on development were observed following administration of dihydroergotamine mesylate during pregnancy (decreased fetal body weight and/or skeletal ossification) in rats and rabbits or during pregnancy and lactation in rats (decreased body weight and impaired reproductive function in the offspring) at doses that were not associated with maternal toxicity (see Data). The estimated rate of major birth defects (2.2% to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy. Data Animal Data Intranasal administration of dihydroergotamine mesylate to pregnant rats throughout the period of organogenesis resulted in decreased fetal body weight and/or skeletal ossification at doses of 0.16 mg/day or greater. A no-effect level for adverse effects on embryofetal toxicity was not identified in rats. Intranasal administration of dihydroergotamine mesylate to pregnant rabbits throughout organogenesis resulted in decreased skeletal ossification at 3.6 mg/day. The no-effect dose for adverse effects on embryofetal toxicity in rabbits was 1.2 mg/day. Intranasal administration of dihydroergotamine mesylate to female rats throughout pregnancy and lactation resulted in decreased body weight and impaired reproductive function (decreased mating indices) in the offspring at doses of 0.16 mg/day or greater. A no-effect dose for adverse developmental effects in rats was not established. Effects on offspring development occurred at doses below those that produced evidence of maternal toxicity in these studies. Dihydroergotamine-induced intrauterine growth retardation has been attributed to reduced uteroplacental blood flow resulting from prolonged vasoconstriction of the uterine vessels and/or increased myometrial tone.

8 USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data, may cause fetal harm. ( 8.1 ) Lactation: Advise not to use during breastfeeding. ( 8.2 ) 8.1 Pregnancy Risk Summary Available data from published literature indicate an increased risk of preterm delivery with dihydroergotamine, the active moiety in BREKIYA, use during pregnancy. Avoid use of BREKIYA during pregnancy [see Warnings and Precautions (5.9) ] . Data collected over decades have shown no increased risk of major birth defects or miscarriage with the use of dihydroergotamine mesylate during pregnancy . In animal reproduction studies, adverse effects on development were observed following administration of dihydroergotamine mesylate during pregnancy (decreased fetal body weight and/or skeletal ossification) in rats and rabbits or during pregnancy and lactation in rats (decreased body weight and impaired reproductive function in the offspring) at doses that were not associated with maternal toxicity (see Data). The estimated rate of major birth defects (2.2% to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy. Data Animal Data Intranasal administration of dihydroergotamine mesylate to pregnant rats throughout the period of organogenesis resulted in decreased fetal body weight and/or skeletal ossification at doses of 0.16 mg/day or greater. A no-effect level for adverse effects on embryofetal toxicity was not identified in rats. Intranasal administration of dihydroergotamine mesylate to pregnant rabbits throughout organogenesis resulted in decreased skeletal ossification at 3.6 mg/day. The no-effect dose for adverse effects on embryofetal toxicity in rabbits was 1.2 mg/day. Intranasal administration of dihydroergotamine mesylate to female rats throughout pregnancy and lactation resulted in decreased body weight and impaired reproductive function (decreased mating indices) in the offspring at doses of 0.16 mg/day or greater. A no-effect dose for adverse developmental effects in rats was not established. Effects on offspring development occurred at doses below those that produced evidence of maternal toxicity in these studies. Dihydroergotamine-induced intrauterine growth retardation has been attributed to reduced uteroplacental blood flow resulting from prolonged vasoconstriction of the uterine vessels and/or increased myometrial tone. 8.2 Lactation Risk Summary There are no data on the presence of dihydroergotamine in human milk; however, ergotamine, a related drug, is excreted in human milk. There are reports of vomiting, diarrhea, weak pulse, and unstable blood pressure in breastfed infants exposed to ergotamine. BREKIYA may reduce milk supply because it may decrease prolactin levels. Because of the potential for reduced milk supply and serious adverse events in the breastfed infant, including diarrhea, vomiting, weak pulse, and unstable blood pressure; advise patients not to breastfeed during treatment with BREKIYA and for 3 days after the last dose. Breast milk supply during this time should be pumped and discarded. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of dihydroergotamine products did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied BREKIYA (dihydroergotamine mesylate) injection is a clear, colorless, sterile solution of 1 mg/mL dihydroergotamine mesylate available as: Dosage Unit Package Size NDC # 1 mL prefilled single-dose autoinjector Carton of 4 NDC 64896-509-02 Caution: The rigid needle shield of the BREKIYA autoinjector contains a needle cover (located inside the cap) that contains dry natural rubber, which is made from latex [see Contraindications (4) and Warnings and Precautions (5.9) ]. 16.2 Storage and Handling Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP controlled room temperature]. Do not refrigerate or freeze. Protect from light. Retain in original pack until time of use.

WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of BREKIYA with strong CYP3A4 inhibitors is contraindicated [see Contraindications (4) , Warnings and Precautions (5.1) , and Drug Interactions (7.1) ]. WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS See full prescribing information for complete boxed warning. Serious and/or life-threatening peripheral ischemia has been associated with the co-administration of dihydroergotamine with strong CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of BREKIYA with strong CYP3A4 inhibitors is contraindicated [see Contraindications (4) and Warnings and Precautions (5.1) ].